The remaining genes, i.e. BLNK [55], MYO7A [56], VNN2 [57], OTOA [58], SLC8A1 [59] and DTX4 [60], might also serve as potential biomarkers for AML. This evidence concerns the gene DTX4 and acute myeloid leukemia.